ClinicalTrials.gg
RecruitingNCT07365592Neo-CDUpdated May 13, 2026

Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC

A Phase 1/2 interventional study of Oxaliplatin and Capecitabine in Colorectal Cancer, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
138
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Colorectal Neoplasms by Second Affiliated Hospital, School of Medicine, Zhejiang University — 19 open to participants now, 20 under way, 2 of them phase 3. Colorectal Neoplasms · Second Affiliated Hospital, School of Medicine, Zhejiang University.

Planned enrollment
6th of 24
138 · median 46
Started
2026
with 4 others
Phase 1/2
2 of 32
2 open now
Primary completion
2029-12
later than 18 of 19 live
Registered
30th of 32
by date

Among the 32 studies in Colorectal Neoplasms by Second Affiliated Hospital, School of Medicine, Zhejiang University, this one is the 6th largest by planned enrollment of the 24 interventional ones that give a count, is one of 5 that started in 2026, is one of 2 in phase 1/2, reaches primary completion later than 18 of the 19 other live ones, and was the 30th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

19 of the 32 studies in Colorectal Neoplasms by Second Affiliated Hospital, School of Medicine, Zhejiang University are open now, in 1 country. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Where they have run

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Colorectal Neoplasms by Second Affiliated Hospital, School of Medicine, Zhejiang University, or all of them as a file.
02

Study summary

This is an open-label, multicenter, phase Ib/II combined trial of sitagliptin, XELOX chemotherapy regimen, and PD-1 monoclonal antibody in the treatment of proficient mismatch repair locally advanced colorectal cancer.

Read the detailed description

Most colorectal cancer (CRC) cases are classified as proficient mismatch repair (pMMR) CRC. This subtype is insensitive to single-agent immunotherapy, with chemotherapy remaining the primary pharmacotherapeutic intervention. Approximately 30% of colon cancer patients develop recurrence and metastasis following initial radical resection combined with 6 months of adjuvant chemotherapy.

Neoadjuvant chemotherapy (NACT) for tumor downstaging and survival improvement represents a standard approach for locally advanced tumors. However, its application is limited to select rectal cancer populations, and its role in colon cancer remains controversial-primarily due to inadequate tumor regression observed with current regimens. Given that deep tumor regression correlates with improved survival, there is a critical need to enhance NACT efficacy.

Neo-CD adopts a combined phase Ib/II study design. Phase Ib Component

  • Design: Single-center trial utilizing the traditional 3+3 dose-escalation principle.
  • Objectives:

    1. Evaluate the safety of sitagliptin in combination with XELOX (oxaliplatin + capecitabine) and anti-PD-1 monoclonal antibody as neoadjuvant therapy for CRC.
    2. Determine the recommended phase II dose (RP2D) of sitagliptin.
    3. Explore the combination's potential for significant tumor regression and modulation of the tumor immune microenvironment.

Phase II Component

  • Design: Prospective, multicenter, randomized controlled superiority trial.
  • Objective: Compare the efficacy of neoadjuvant XELOX + sitagliptin + anti-PD-1 versus standard neoadjuvant XELOX in locally advanced CRC, with a focus on significant tumor regression (TRG 0/1 rate).

Study Procedures All participants will receive 2 cycles of the assigned neoadjuvant treatment, followed by radical surgery.

Primary Endpoints

  • Phase Ib: Incidence of adverse events (AEs), serious adverse events (SAEs), and dose-limiting toxicity (DLT).
  • Phase II: Proportion of patients achieving tumor regression grade 0/1 (TRG 0/1).
03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosed colorectal adenocarcinoma
  • Age ≥18 years old and ≤75 years old
  • MRI/CT stage T3-4aNany and TanyN1-2, without distant
  • of 1 year The above
  • , no to chemotherapy exist
  • pMMR diagnosed by IHC

Exclusion criteria

Exclusion Criteria:

  • Refused to participate in this study
  • Multifocal colorectal cancer
  • Past history of malignant tumors, except for basal cell carcinoma/papillary thyroid carcinoma/various types of carcinoma in situ
  • Unable to receive chemotherapy , such as but not limited to bone marrow suppression, etc
  • Major organ diseases (such as but not limited to , coronary heart disease and renal insufficiency, etc.) acute attack and or severe acute infectious diseases (such as but not limited to hepatitis, pneumonia and myocarditis, etc.),
  • > 3
  • Mental disorder or illiteracy or language and communication barriers cannot understand the research plan
  • Colorectal tumor has obstruction or high risk of obstruction and or there is bleeding and/or perforation
  • Peripheral sensory nerve disorder, unable to receive oxaliplatin chemotherapy
  • Lateral pelvic lymph node (mainly supplied by internal iliac artery)
  • Pregnancy or breastfeeding
  • Unable to accept MRI examination
  • Consecutive use of for more than 3 days within 1 month before signing the consent form
  • Diabetes or impaired glucose tolerance who may require drug intervention
  • Other scenarios deemed inappropriate by the investigators
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
138 participants (estimated)

Study arms

  • Experimental
    XELOX+sitagliptin+anti-PD-1

    XELOX (oxaliplatin + capecitabine), sitagliptin and PD-1 monoclonal antibody

    Drug: Oxaliplatin · Drug: Capecitabine · Drug: Anti-PD-1 monoclonal antibody · Drug: Sitagliptin (DPP4 inhibitor)

  • Active comparator
    XELOX

    XELOX (oxaliplatin + capecitabine)

    Drug: Oxaliplatin · Drug: Capecitabine

Interventions

  • Oxaliplatin 130mg/m2 for inducing chemotherapy in Day 1 every 3 weeks and repeat for two cycles.

  • Oral Capecitabine 1000 mg/m2 twice daily combined with oxaliplatin chemotherapy in Day 1 to Day 14 every 3 weeks and repeat for 2 cycles.

  • Anti-PD1 antibody 200mg/m2 in Day 1 after oxaliplatin Chemotherapy. Repeat every 3 weeks for 2 cycles.

  • DrugSitagliptinStudies of SitagliptinSitagliptin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oral sitagliptin twice daily combined with oxaliplatin chemotherapy in Day 1 to Day 14 every 3 weeks and repeat for 2 cycles. In the phase Ib study, sitagliptin set at three dose groups: 100 mg/day, 200 mg/day, and 400 mg/day, and the primary endpoint of Ib study is to determine the DLT and recommended phase II dose (RP2D). The appropriate dose level of sitagliptin will be set based on the result of Ib study.

06

What researchers measure

Primary outcomes

  1. Adverse events (AEs)

    for Ib study

    Time frame: From date of first chemotherapy until the date of patients were discharged from hospital after receiving radical surgery, up to 20 weeks

  2. Dose limiting toxicities (DLTs)

    for Ib study

    Time frame: The DLT observation period is from the day1 of the first cycle(C1D1) to the start of the day1 of the second cycle(C2D1) dosing, each cycle is 21 days.

  3. Proportion of patients achieving tumor regression grade 0/1 (TRG 0/1)

    for II study

    Time frame: 1 day of postoperative pathological examination.

Secondary outcomes

  1. Surgical Complication

    for II study

    Time frame: within 30 days since operation

  2. Proportion of patients achieving tumor regression grade 3 (TRG 3)

    for II study

    Time frame: 1 day of postoperative pathological examination.

  3. Adverse events (AEs)

    for II study

    Time frame: From date of first chemotherapy until the date of patients were discharged from hospital after receiving radical surgery, up to 20 weeks

  4. Proportion of patients achieving tumor regression grade 0/1

    for Ib study

    Time frame: 1 day of postoperative pathological examination.

  5. Proportion of patients achieving pathological Complete Response

    for Ib study

    Time frame: 1 day of postoperative pathological examination.

  6. Proportion of patients achieving Major Pathologic Response

    for Ib study

    Time frame: 1 day of postoperative pathological examination.

  7. Area Under the Curve

    for Ib study;quantitative measure of the total exposure of the body to a drug over a specific time period.

    Time frame: From date of first chemotherapy until the date of patients were discharged from hospital after receiving radical surgery, up to 20 weeks

  8. Maximum Concentration

    for Ib study; highest plasma or blood concentration of a drug achieved in the body after its administration.

    Time frame: From date of first chemotherapy until the date of patients were discharged from hospital after receiving radical surgery, up to 20 weeks

  9. Time to Maximum Concentration

    for Ib study; the length of time required for a drug to reach its maximum (peak) plasma or blood concentration in the systemic circulation after administration.

    Time frame: From date of first chemotherapy until the date of patients were discharged from hospital after receiving radical surgery, up to 20 weeks

  10. Clearance

    for Ib study; the volume of plasma or blood completely cleared of a drug per unit time by the body's eliminating organs

    Time frame: From date of first chemotherapy until the date of patients were discharged from hospital after receiving radical surgery, up to 20 weeks

  11. Half-Life

    for Ib study; the specific time required for the plasma or blood concentration of a drug in the systemic circulation to decrease by half from its peak level or steady-state level

    Time frame: From date of first chemotherapy until the date of patients were discharged from hospital after receiving radical surgery, up to 20 weeks

Other outcomes

  1. DPP4 activity in peripheral blood and tumor tissues

    for Ib study;

    Time frame: From date of first chemotherapy until the date of patients were discharged from hospital after receiving radical surgery, up to 20 weeks

  2. The changes in the immunoprofile of the tumor tissue sample among TRG0/1 and TRG2/3 patients

    By using single-cell analysis, we comprehensively characterized the immune landscape in the tumor sample of CRC patients before and after neoadjuvant treatment.

    Time frame: 3 months after surgery

  3. 2-year overall survival

    for II study; The proportion of all study cases in which no death from any cause occurred within 2 years after surgery

    Time frame: 2-year after surgery

  4. 2-year Disease-free survival

    From date of first chemotherapy until the date of first documented recurrence of tumor or date of death from any cause,whichever came first,assessed up to 24 months.

    Time frame: From date of first chemotherapy until the date of first documented recurrence of tumor or date of death from any cause,whichever came first,assessed up to 24 months.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Dec 2029, 43 months after the start.

Of 102 non-industry phase 1/2 interventional studies under Colorectal Neoplasms, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 106. This study's planned 43 months is below that.

Counting every sponsor, half of 261 studies reached it within 59 months; a quarter within 36 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2025
First posted
Jan 26, 2026
StartActual
Apr 9, 2026
Primary completionEst.
Dec 1, 2029
CompletionEst.
Dec 31, 2029
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07365592
Responsible party
Jun Li (Chief, Second Affiliated Hospital, School of Medicine, Zhejiang University) — Principal investigator
First posted
Jan 26, 2026
Start date
Apr 9, 2026
Primary completion
Dec 1, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
May 13, 2026

Study contacts

Jun Li, MD
Contact
2307016@zju.edu.cn
+86 13777878061
Xinyi Zhou, MD
Contact
3100102575@zju.edu.cn
+86 18768115468

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Anti-PD1 Monoclonal Antibody · Sitagliptin

Start the discussion